Table 2.
Microbiology of patients with device-associated osteomyelitis treated with daptomycin in the CORE database
| Pathogens, n (%)a | No follow-up in CORE 2009 | Evaluable population | |
|---|---|---|---|
| PJI | OHAO | ||
| (n = 32) | (n = 27) | (n = 21) | |
| Staphylococcus aureus (MRSA) | 9 (28.1) | 6 (22.2) | 7 (33.3) |
| Staphylococcus aureus (MSSA) | 2 (6.3) | 3 (11.1) | 4 (19.0) |
| Other Staphylococcus aureus b | 1 (3.1) | 1 (3.7) | 0 (0.0) |
| Coagulase-negative staphylococci | 3 (9.4) | 6 (22.2) | 3 (14.3) |
| Enterococcus spp. | 4 (12.5) | 3 (11.1) | 3 (14.3) |
| Vancomycin-resistant enterococci | 1 (3.1) | 1 (3.7) | 2 (9.5) |
| Streptococcus spp. | 0 (0.0) | 0 (0.0) | 1 (4.8) |
| Other | 7 (21.9) | 3 (11.1) | 1 (4.8) |
CORE Cubicin® Outcomes Registry and Experience, MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, OHAO other hardware-associated osteomyelitis, PJI prosthetic joint infection
aPatients may have had more than one pathogen
bOther S. aureus includes methicillin susceptibility unknown